Today's News |
Sirona Biochem Launches Cosmetics Subsidiary Sirona Laboratories to Commercialize its Anti-Aging Skincare Ingredient GlycoProteMim.
Thursday, January 18, 2024Company Profile | Follow Company
Vancouver, BC, January 18, 2024--(T-Net)--Sirona Biochem Corp. (TSX-V: SBM) announced today Sirona Laboratories - a new wholly-owned subsidiary dedicated to maximizing the commercial potential of its breakthrough anti-aging skincare ingredient, GlycoProteMim™.
Dr. Howard Verrico, CEO and founder of Sirona Biochem, expressed his enthusiasm for the major milestone, stating that the establishment of Sirona Laboratories is meant to not just shape the future of the company, but to revolutionize the global anti-aging skincare market.
The announcement follows the recent decision to trademark GlycoProteMim.
The extraordinary results from the active ingredient's clinical trials prompted the company's strategic decision to establish Sirona Laboratories, which will redefine its trajectory in the skincare industry.
Howard J. Verrico, MD, CEO and Chairman of the Board, Sirona Biochem Corp.
"We've opted for a course of action that - is primed to transform, not just Sirona Biochem's prospects, but that of the entire anti-aging market. We're not just interested in GlycoProteMim's value today; we want to build its legacy and set a global precedent. This isn't just about proving its efficacy; it's about setting a new benchmark for anti-aging skin treatments," Verrico said.
Sirona Biochem said in a release that it is inviting major industry players to take notice, to partner, and to believe in a future where GlycoProteMim is the go-to ingredient for skin anti-aging.
As part of the strategic leap into the aesthetic marketplace, Sirona Biochem says it plans to position itself for maximum growth and market expansion.
Christopher Hopton CPA, Chief Financial Officer, Sirona Biochem
Christopher Hopton CPA, Chief Financial Officer of Sirona Biochem, commented on the launch, stating that the strategic decision aligns with the company's commitment to shareholder value, innovation, and market leadership.
"By establishing Sirona Laboratories, we are not only maximizing the commercial potential of GlycoProteMim but also ensuring sustained growth and value creation for our shareholders," Hopton added.
Dr. Geraldine Deliencourt-Godefroy, Chief Scientific Officer, Sirona Biochem
Dr. Geraldine Deliencourt-Godefroy, Chief Scientific Officer at Sirona Biochem, said "The company's clinically proven science, combined with the unmet commercial opportunity, positions Sirona Laboratories at the forefront of skincare innovation. We are eager to leverage our expertise and take GlycoProteMim to new heights, while also setting a new benchmark for anti-aging treatments," she said.
To support this initiative, the company said that it has already identified a team of seasoned industry experts who will play a crucial role in steering Sirona Laboratories toward success.
The company is actively engaging with private equity funds and collaborating with industry experts to develop Sirona Laboratories product line and commercial strategy.
The company intends to finance the bulk of this project through private financial partnerships, while leveraging its parent company's intellectual property.
Sirona Biochem aims to propel the subsidiary, which will be based in Europe, and its active ingredient into a new era of global recognition.
About Sirona Biochem
Sirona Biochem is a leading biotech company with a proprietary formulation platform technology. Specializing in cosmetic ingredients and drug discovery, Sirona Biochem has developed a process to stabilize carbohydrate molecules, improving efficacy and safety for different applications.
Sirona's compounds are licensed to leading cosmetics and pharma companies worldwide, in return for licensing fees, milestone payments, and ongoing royalty payments. Sirona's R&D unit laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. [ MORE ] |
Other Recent Company News |
|||||||||||||||||||
|